In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...

GSK stock declined 3% despite beating Q1 earnings estimates. Analysts note legal provisions contributed half the beat.

A concept presented by NASA March 24 calls for the agency to procure a module attached to the ISS that could serve as the core of a commercial station. Credit: NASA WASHINGTON — NASA, concerned about ...

-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) ...

FDA expansion of the Arexvy vaccine provides protection against RSV-related lower respiratory tract disease for at-risk adults aged 18 to 49 years. The Food and Drug Administration (FDA) has expanded ...

What Is Arexvy, and Why Does It Matter? Arexvy is a vaccine that helps protect against serious lung illness caused by respiratory syncytial virus (RSV). The FDA has expanded its use to include people ...

Please provide your email address to receive an email when new articles are posted on . GSK’s Arexvy became the third RSV vaccine approved for high-risk adults aged younger than 50 years. The CDC has ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

GSK (GSK) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for its Arexvy vaccine against the Respiratory Syncytial Virus (RSV) to allow its use for ...

Indication for AREXVY AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: individuals 60 ...